Bayer Detailed Consensus >> Segments
Consensus as of: 2026-09-01

Please note:

  • Historic numbers for FY 2025 are restated according to the new Core EPS methodology
  • The estimates for FY 2026-30 are taking the new Core EPS methodology into account as well

KPI[EUR m]FY 2025FY 2026 EFY 2027 EFY 2028 EFY 2029 EFY 2030 E
Pharmaceuticals, SalesNumber of Estimates1817171412
Pharmaceuticals, SalesHighest18,02219,09920,20221,56223,562
Pharmaceuticals, SalesAverage17,82917,80418,40919,12619,95420,954
Pharmaceuticals, SalesMedian17,79918,46419,35020,39521,628
Pharmaceuticals, SalesLowest17,55917,57617,54916,40815,537
XareltoNumber of Estimates1414141211
XareltoHighest1,5291,2231,092884840
XareltoAverage2,3441,3981,010829694611
XareltoMedian1,3851,045865745610
XareltoLowest1,318655495415370
EyleaNumber of Estimates1414141210
EyleaHighest2,5312,2782,1641,9201,859
EyleaAverage3,1102,2882,0091,7971,5821,522
EyleaMedian2,2972,0261,7801,6341,524
EyleaLowest2,1491,6331,2256131,258
Nubeqa & KerendiaNumber of Estimates1414141211
Nubeqa & KerendiaHighest5,2386,4777,4918,4109,217
Nubeqa & KerendiaAverage3,2144,9116,1187,0107,5788,254
Nubeqa & KerendiaMedian4,8926,1677,0867,7078,527
Nubeqa & KerendiaLowest4,6975,7156,2106,1976,094
NubeqaNumber of Estimates1414141211
NubeqaHighest3,7634,6205,3985,6756,061
NubeqaAverage2,3853,5904,3614,8595,0705,373
NubeqaMedian3,5884,3394,9064,9675,196
NubeqaLowest3,4244,1114,4874,6314,765
Kerendia (Finerenone)Number of Estimates1414141211
Kerendia (Finerenone)Highest1,4751,9352,4933,3694,042
Kerendia (Finerenone)Average8291,3211,7572,1512,5082,881
Kerendia (Finerenone)Median1,3161,7362,1492,5992,938
Kerendia (Finerenone)Lowest1,2441,5461,6231,3811,158
New Launch AssetsNumber of Estimates88887
New Launch AssetsHighest3908831,5702,4003,200
New Launch AssetsAverage02846611,1401,6632,340
New Launch AssetsMedian2897151,2091,7052,316
New Launch AssetsLowest1802824606271,505
Lynkuet (Elinzanetant)Number of Estimates101010109
Lynkuet (Elinzanetant)Highest1804978261,2011,518
Lynkuet (Elinzanetant)Average0134276440613802
Lynkuet (Elinzanetant)Median150265378535712
Lynkuet (Elinzanetant)Lowest75142224324396
AsundexianNumber of Estimates101010109
AsundexianHighest903206751,3501,800
AsundexianAverage012118305520814
AsundexianMedian0129335515748
AsundexianLowest00000
Beyonttra (acoramidis)Number of Estimates88887
Beyonttra (acoramidis)Highest220363545762839
Beyonttra (acoramidis)Average0136237356467594
Beyonttra (acoramidis)Median124231339478612
Beyonttra (acoramidis)Lowest85140210248382
Base BusinessNumber of Estimates88887
Base BusinessHighest9,4579,3539,65810,27911,612
Base BusinessAverage9,1629,0508,8268,7778,8329,074
Base BusinessMedian9,0448,8168,7368,7238,829
Base BusinessLowest8,7658,4338,1517,9277,735
t/o IUD FamilyNumber of Estimates1313131211
t/o IUD FamilyHighest1,4211,4621,5301,6061,687
t/o IUD FamilyAverage1,3661,3751,4001,4161,4291,436
t/o IUD FamilyMedian1,3791,4071,3871,3971,407
t/o IUD FamilyLowest1,3281,3361,3361,3331,310
t/o HEM Franchise Number of Estimates1313131211
t/o HEM Franchise Highest582553531510489
t/o HEM Franchise Average613540496460419379
t/o HEM Franchise Median535501473422391
t/o HEM Franchise Lowest512410369307238
t/o AdalatNumber of Estimates1414141110
t/o AdalatHighest679676674671668
t/o AdalatAverage503546534524534535
t/o AdalatMedian550540537531531
t/o AdalatLowest469443409401380
t/o Aspirin CardioNumber of Estimates1313131110
t/o Aspirin CardioHighest514658644642642
t/o Aspirin CardioAverage516463472469484477
t/o Aspirin CardioMedian461468476485488
t/o Aspirin CardioLowest408359316336303
t/o AdempasNumber of Estimates1414141211
t/o AdempasHighest763776815770778
t/o AdempasAverage745724546441318283
t/o AdempasMedian730518375289250
t/o AdempasLowest661311192134128
Pharmaceuticals, EBITDA before special itemsNumber of Estimates1716161311
Pharmaceuticals, EBITDA before special itemsHighest4,4554,7755,3536,0376,813
Pharmaceuticals, EBITDA before special itemsAverage4,5254,3084,5514,9335,4435,989
Pharmaceuticals, EBITDA before special itemsMedian4,3424,5324,9885,6416,359
Pharmaceuticals, EBITDA before special itemsLowest3,9844,2824,2654,2814,330
Consumer Health, SalesNumber of Estimates1817171311
Consumer Health, SalesHighest6,0096,1686,3956,5506,782
Consumer Health, SalesAverage5,8025,8966,0736,2506,4436,618
Consumer Health, SalesMedian5,9006,0866,2696,4676,661
Consumer Health, SalesLowest5,7115,8826,0196,2096,375
Consumer Health, EBITDA before special itemsNumber of Estimates1716161210
Consumer Health, EBITDA before special itemsHighest1,4021,5371,6121,6711,718
Consumer Health, EBITDA before special itemsAverage1,3411,3371,4351,4951,5631,627
Consumer Health, EBITDA before special itemsMedian1,3431,4331,4811,5551,631
Consumer Health, EBITDA before special itemsLowest1,2851,3711,4001,4931,533
CropScience, SalesNumber of Estimates1817171311
CropScience, SalesHighest22,32823,39023,83725,04625,756
CropScience, SalesAverage21,62221,80322,33123,02023,90524,627
CropScience, SalesMedian21,78622,29823,18924,06124,894
CropScience, SalesLowest21,23221,31121,61121,92722,258
CropScience, EBITDA before special itemsNumber of Estimates1716161210
CropScience, EBITDA before special itemsHighest5,0315,3345,7786,2526,440
CropScience, EBITDA before special itemsAverage4,1884,6464,8525,1995,5915,801
CropScience, EBITDA before special itemsMedian4,6624,8325,1435,5045,788
CropScience, EBITDA before special itemsLowest4,2644,5954,8174,9135,079
Reconciliation, SalesNumber of Estimates1817171311
Reconciliation, SalesHighest365375386368376
Reconciliation, SalesAverage322315307309313322
Reconciliation, SalesMedian322322322322322
Reconciliation, SalesLowest279208220238238
Reconciliation, EBITDA before special itemsNumber of Estimates1616161210
Reconciliation, EBITDA before special itemsHighest-390-368-373-378-378
Reconciliation, EBITDA before special itemsAverage-385-551-494-496-506-520
Reconciliation, EBITDA before special itemsMedian-569-500-500-500-500
Reconciliation, EBITDA before special itemsLowest-600-606-612-618-625
Disclaimer

This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.